Moderna’s Maternal RSV Vaccine Study Reaches Completion: What Investors Should Watch
Moderna (MRNA) announced an update on their ongoing clinical study.
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
ModernaTX, Inc. (MRNA) is running a Phase 2 trial called “A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers.” The study tests if its RSV shot is safe, well tolerated, and able to trigger an immune response in mothers and their babies, a key step toward a maternal RSV franchise.
The treatment is mRNA-1345, an mRNA vaccine given as a single muscle shot between 28 and 36 weeks of pregnancy. A saline placebo is used as a control, letting researchers compare safety and immune effects against a neutral baseline.
The trial is interventional and randomized, meaning volunteers are assigned by chance to vaccine or placebo. It uses a parallel, observer-blind design with both participants and study staff masked, and the main goal is to see if the shot can help prevent RSV disease in this high-risk setting.
The study was first submitted on 14 November 2023, marking its formal launch into the clinical database. The record was last updated on 8 June 2026, signaling that Moderna has refreshed details after the study reached completed status and moved closer to possible data disclosure.
For investors, a completed maternal RSV study is a visible de-risking event for MRNA, supporting its plan to diversify beyond COVID. Strong safety and immune data could lift sentiment and valuation versus RSV rivals like GSK and Pfizer, while weak results would likely push investors toward better positioned vaccine names.
The Moderna maternal RSV trial of mRNA-1345 is now listed as completed and recently updated, with more information available on the ClinicalTrials portal.
To learn more about MRNA’s potential, visit the Moderna drug pipeline page.
